For a long time the debate about screening for prostate cancer has focused on the trade off between potential benefits (lives saved) and harms (overdiagnosis, overtreatment), although quantifying either is proving difficult. …
Get access to this article and to all of thebmj.com for 14 days.
Sign up today for a 14 day free trial.
Access to the full version of this article requires a subscription payment.